Analyzing Vivos (OTCMKTS:RDGL) & Profound Medical (NASDAQ:PROF)

Vivos (OTCMKTS:RDGL) and Profound Medical (NASDAQ:PROF) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for Vivos and Profound Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos	0	0	0	0	N/A
Profound Medical	0	1	1	1	3.00

Profound Medical has a consensus price target of $12.63, indicating a potential upside of 35.75%. Given Profound Medical’s higher possible upside, analysts plainly believe Profound Medical is more favorable than Vivos.

Profitability

This table compares Vivos and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos	-8,049.36%	N/A	-121.18%
Profound Medical	-423.75%	-55.78%	-46.43%

Earnings and Valuation

This table compares Vivos and Profound Medical’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos	$40,000.00	578.08	-$2.47 million	N/A	N/A
Profound Medical	$6.68 million	30.59	-$28.67 million	($1.37)	-7.01

Vivos has higher earnings, but lower revenue than Profound Medical.

Institutional & Insider Ownership

35.9% of Profound Medical shares are held by institutional investors. 18.5% of Vivos shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Vivos has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Summary

Profound Medical beats Vivos on 7 of the 12 factors compared between the two stocks.

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.